Pazufloxacin Mesylate

甲磺酸帕珠沙星

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NamePazufloxacin Mesylate
Drug Alias NamePazufloxacinum帕苏沙星帕珠沙星甲磺酸盐Pazufloxacino帕珠沙星 +[15] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Quinolone antibiotics
Mechanisms of ActionBacterial DNA gyrase inhibitorsTopoisomerase IV inhibitors
TargetsTopoisomerase IVBacterial DNA gyrase
Therapy Area/IndicationsParametritisAdnexal DiseasesCystitis +[26] 
Global Approved IndicationsParametritisAdnexal DiseasesCystitis +[22] 
Approved Indications in ChinaCommunicable Diseases
Original Approved Country/TerritoryJapan
Original Approved Date2002/04/11
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTaisho Toyama
China Registration ClassN/A

Develop Information

Active CompaniesTaisho ToyamaMitsubishi Tanabe PharmaGuangzhou Boji New Medicine Clinic Research Center +[4] 
Inactive CompaniesLee'S Pharmaceutical Ltd
Active IndicationsParametritisAdnexal DiseasesCystitis +[26] 
Inactive IndicationsN/A

Other Information

ATC CodeJ01MA18
Related LinksWikipediaKEGG